Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Chief Scientific Officer | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 158,844 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 4,000 · Balance 166,844 Row 2 · 2026-09-08 · Sale · Disposed 8,000 · Balance 158,844 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28 | Direct | 78,987 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 4,000 · Balance 78,987 F3: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $21.57 | $172,560.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.31 to $21.83. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 13:22 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-387381 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,987 Underlying: Common Stock · 30,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 30,000 | $20.26 | $607,800.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 30,000 | $4.30 | $129,000.00 |
DisclosureSEC source: 0001193125-26-352523 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $17.82 | $142,560.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.35 to $18.19. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-297605 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 200 | $15.58 | $3,116.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.56 to $15.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 7,800 | $14.60 | $113,880.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,044 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.24 to $15.12. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 6, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-209307 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · derivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,987 Underlying: Common Stock · 4,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $15.68 | $125,440.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.38 to $16.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 4,000 | $4.30 | $17,200.00 |
DisclosureSEC source: 0001193125-26-098781 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 22:05 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,780 | $14.14 | $25,169.20 |
DisclosureSEC source: 0001193125-26-077259 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,844 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.89 to $14.35. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,601 | $14.47 | $52,106.47 |
DisclosureSEC source: 0001193125-26-072002 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,624 F3 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,752 | $13.99 | $24,510.48 |
DisclosureSEC source: 0001193125-26-072002 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,225 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.68 to $14.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · derivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,987 Underlying: Common Stock · 8,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $14.30 | $114,400.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,977 F2 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 8,000 | $4.30 | $34,400.00 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,742 | $13.62 | $50,966.04 |
DisclosureSEC source: 0001193125-26-064256 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,977 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001193125-26-059636 · ownership.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059636 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,719 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 416 | $12.03 | $5,004.48 |
DisclosureSEC source: 0001193125-26-051700 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,219 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,000 | $12.30 | $49,200.00 |
DisclosureSEC source: 0001193125-26-021225 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,635 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 1,345 | $10.01 | $13,463.45 |
DisclosureSEC source: 0001193125-25-328909 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,635 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.99 to $10.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 2,898 | $9.67 | $28,023.66 |
DisclosureSEC source: 0001193125-25-327027 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,980 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 995 | $11.90 | $11,840.50 |
DisclosureSEC source: 0001193125-25-321122 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,878 F3 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 2,148 | $12.38 | $26,592.24 |
DisclosureSEC source: 0001193125-25-321122 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,873 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. F2 · balance_after: Includes 2,017 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,000 | $12.30 | $49,200.00 |
DisclosureSEC source: 0001193125-25-297549 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,004 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,756 | $8.53 | $32,038.68 |
DisclosureSEC source: 0000950170-25-029200 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,004 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000950170-25-025032 · ownership.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-025032 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,760 F1 · shares: The shares underlying the restricted stock unit vest on an annual basis over four years. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,000 | $12.51 | $50,040.00 |
DisclosureSEC source: 0000950170-25-002946 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.32 to $12.62. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 4,693 | $11.41 | $53,547.13 |
DisclosureSEC source: 0000950170-24-139125 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,760 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 3,489 | $12.52 | $43,682.28 |
DisclosureSEC source: 0000950170-24-136726 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,453 F1 · kind: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 22:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $15.64 | $125,120.00 |
DisclosureSEC source: 0000950170-24-123538 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,942 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.25 to $15.98. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2024 Filed Sep 9, 2024 21:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $18.09 | $144,720.00 |
DisclosureSEC source: 0000950170-24-104820 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,942 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.79 to $18.55. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 21:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 8,000 | $16.33 | $130,640.00 |
DisclosureSEC source: 0000950170-24-082485 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,942 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.97 to $16.77. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 2,360 | $9.00 | $21,240.00 |
DisclosureSEC source: 0000950170-24-080961 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,942 F2 · price: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2024. F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 07, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,606 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · derivative · entry 7 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,987 Underlying: Common Stock · 5,606 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 07, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 5,606 | $30.06 | $168,516.36 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · nonDerivative · entry 5 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,582 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 5,606 | $4.30 | $24,105.80 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · nonDerivative · entry 4 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · derivative · entry 6 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,593 Underlying: Common Stock · 50,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares vested on July 4, 2020, and the remaining shares vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 20,277 | $28.54 | $578,705.58 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · nonDerivative · entry 3 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,582 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.35 to $28.84. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | SaleCommon Stock | 37,723 | $27.82 | $1,049,453.86 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · nonDerivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,859 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.35 to $28.34. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:30 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 50,000 | $4.30 | $215,000.00 |
DisclosureSEC source: 0000950170-24-056093 · ownership.xml · nonDerivative · entry 1 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0000950170-24-019456 · ownership.xml · derivative · entry 2 Michaelson Jennifer · CIK 0001838061 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-22 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.